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There are well-known side effects of chemotherapy and radiotherapy that are mainly related to the toxicity and
impaired function of vital organs; however, the induction by these therapies of expression of several pro-metastatic
factors in various tissues and organs that in toto create a pro-metastatic microenvironment is still, surprisingly, not
widely acknowledged. In this review, we support the novel concept that toxic damage in various organs leads to
upregulation in “bystander” tissues of several factors such as chemokines, growth factors, alarmines, and bioactive
phosphosphingolipids, which attract circulating normal stem cells for regeneration but unfortunately also provide
chemotactic signals to cancer cells that survived the initial treatment. We propose that this mechanism plays an
important role in the metastasis of cancer cells to organs such as bones, lungs, and liver, which are highly
susceptible to chemotherapeutic agents as well as ionizing irradiation. This problem indicates the need to develop
efficient anti-metastatic drugs that will work in combination with, or follow, standard therapies in order to prevent
the possibility of therapy-induced spread of tumor cells.
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The results of conditioning strategies for bone marrow
(BM) transplantation by employing myelo- or submyeloa-
blative doses of chemotherapy or radiotherapy provides
evidence that damage of the BM environment results in
upregulation of several factors that direct chemottraction
and homing of hematopoietic stem progenitor cells
(HSPCs) to BM. The most important homing signal re-
sponsible for this effect is mediated by α-chemokine
stromal-derived factor 1 (SDF-1) [1,2]. The biological effect
of this chemokine is supported by other factors, including
bioactive phosphosphingolipids such as sphingosine-1-
phosphate (S1P) and ceramide-1-phosphate (C1P) [3-7], as
well as some members of a family of alarmines, including
extracellular nucleotides such as ATP and UTP [8,9], that
are released from damaged and “leaky” BM cells. All these* Correspondence: mzrata01@louisville.edu
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stated.factors direct migration and translocation of HSPCs circu-
lating in peripheral blood (PB) into BM niches. Moreover,
the same factors are known to be upregulated in organs
damaged by hypoxia, as seen in acute myocardial infarc-
tion, stroke, ischemic kidney damage, or toxic liver injury,
which chemoattract normal circulating stem cells for po-
tential tissue/organ regeneration [10-14].
At the same time, all these factors are very well-known
chemoattractants for several types of malignant cells and
are involved in formation of distant metastases [15-20]. It
is well known that metastases are responsible for more
than 90% of tumor-associated mortality and thus are a
crucial problem for developing more efficient and success-
ful cancer therapies. Depending on the tumor type and
microenvironment, as postulated 125 years ago by Paget
in a famous “seed and soil hypothesis” [21,22], tumor cells
have a preference for metastasizing to “tumor-receptive”
organs. This receptiveness depends on a repertoire of che-
moattractants secreted in a given tissue as well as expres-
sion of corresponding receptors on the surface of theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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also played by tumor cell-expressed adhesion molecules
that anchor circulating tumor cells to the endothelium at
the site of the distant metastasis [23,24].
One of the most important questions in oncology re-
mains the true nature of the tumor cells that are
endowed with migratory and thus metastatic properties.
It is obvious that most growing tumors are composed of
malignant cells that show different levels of maturation.
Usually in a growing solid tumor, the more differentiated
cells are seen in its central areas, and more primitive
cells endowed with migratory/infiltration properties are
encountered on the periphery [25].
According to accumulating evidence, the rarest tumor
cells are cancer stem cells (CSCs), which are more resistant
to treatment by standard therapies and, like most normal
stem cells during embryogenesis, are strongly endowed
with migratory properties [26-32]. Another possibility that
has been postulated as a source of metastatic cancer cells
is the epithelial-to-mesenchymal transition (EMT), in
which some tumor cells, by changing their genetic pro-
gram, become highly migratory cells [30,33-35]. Thus, as is
currently speculated, both of these processes - the presence
of CSCs in the growing tumor as well EMT - may drive
tumor metastasis and are responsible for tumor dissemin-
ation to distant organs.
Lessons from normal circulating stem cells during tissue/
organ injury
One of the important features of early-development stem
cells is their propensity to migrate, which is clearly seen
for many types of stem cells during processes such as gas-
trulation and subsequent organ development [36-39].
Later on in adult life, some types of stem cells are still
highly migratory and are mobilized into peripheral blood
(PB) and lymph, migrating to distant locations [40,41].
The best examples for such stem cells are hematopoietic
stem progenitor cells (HSPCs) [36,42], endothelial pro-
genitor cells (EPCs) [43], mesenchymal stromal cells
(MSCs) [44], and very small embryonic-like stem cells
(VSELs) [45].
It is well known that all of these types of stem/progeni-
tor cells are detectable under steady-state conditions in PB
and lymph, and their number increases, for example,
during organ damage or inflammation [46]. In all these
situations, damaged tissues release potent chemotactic fac-
tors that direct trafficking of these cells. These pro-
chemotactic compounds belong to families of chemokines,
growth factors, bioactive lipids, and some small molecules
known as alarmines [7-9,17]. Chemokines and some pro-
angiopoietic growth factors are released from the damaged
tissues in response to damage-related hypoxia involving
hypoxia-inducible factor 1 alpha (HIF-1α) [47] activation
of transcription of genes encoding chemokines (e.g., SDF-1; interleukin 8, IL-8) [48-51] and selected growth factors
(e.g., vascular endothelial growth factor, VEGF) that are
primarily involved in promoting vascularization of dam-
aged organs.
Also released from damaged cells during tissue/organ
injury are so-called alarmines or damage-associated
molecular pattern molecules (DAMPs, also known as
danger-associated molecular pattern molecules), which
can initiate and perpetuate immune responses and subse-
quent repair processes [52,53]. The most important mole-
cules from this family of mediators are purine metabolites,
including nucleotides (e.g., ATP and UTP) [54,55], the
chromatin-associated protein high-mobility group box 1
(HMGB1) [56-58], and S100 molecules, which belong to a
multigenic family of calcium-modulated proteins [59-61].
All these molecules are released from damaged cells and,
after they have reached the extracellular space, serve as
“danger” signals. Finally, accumulating evidence suggests a
role for bioactive phosphosphingolipids such as S1P and
C1P in regulating trafficking of stem/progenitor cells. As
we recently demonstrated, both S1P and C1P direct mi-
gration of HSPCs, MSCs, EPCs, and VSELs [7].
It is very likely that a proper repertoire of these factors
upregulated in damaged tissues is important for mobilization
into PB and subsequent homing to the damaged organs
of specific subsets of circulating stem progenitor cells
[62]. In support of this possibility, VEGF more select-
ively mobilizes EPCs into PB [63].
Release of normal stem cells into circulation and their
subsequent homing into damaged tissues may play some
role in regeneration of organs damaged by chemother-
apy or radiotherapy. The beneficial effects of stem cells
in regeneration of damaged tissues are mainly based on
the paracrine effects of circulating stem cells [64-66] as
well as some more direct effects such as for example
their contribution to vasculogenesis [67].
Circulating tumor cells
Unfortunately, it is well known that, like normal stem
cells, cancer cells also circulate in PB and lymph and
may be seeded to distant tissues. Evidence has even ac-
cumulated that these circulating cancer cells may be
already present at locations distant from the tumor at
very early stages of tumor development [68]. As a
population of de-differentiated and transformed normal
cells, the propensity of tumor cells to migrate most
likely reflects the migratory nature of normal early-
development stem cells. This propensity may be particu-
larly important for the population of most-primitive can-
cer cells present in the growing tumor known as CSCs
[26,27,29,32,69] or cancer cells endowed with migratory
properties characteristic of mesenchymal cells generated
in the process of EMT, which in consequence leads to for-
mation of disseminating tumor cells (DTCs) [30,31].
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respond to a similar repertoire of chemoattractants as
normal cells circulating in PB. Extravasation of malig-
nant cells to the sites of metastasis depends also on ex-
pression on their surface of adhesion molecules that
may tether them to endothelium as well as expression of
proteolytic enzymes such as various metalloproteinases
(MMPs) that facilitate their migration and infiltration in
the tissues [24,70,71]. Some evidence has accumulated
that a metastasis-permissive microenvironment at a fu-
ture site of metastasis has already been created some
time before “arrival” of new unwanted inhabitants, CSCs
or DTCs [61,72-74]. Moreover, it has even been also
postulated that, in some cases, BM-derived cells are in-
volved in induction of this pro-metastatic microenviron-
ment at distant locations [61,72].
Therefore, despite significant reduction of tumor mass
with initial treatment, some cancer cells more resistant
to radiotherapy and chemotherapy (e.g., CSCs) may sur-
vive and after treatment respond to chemotactic cues in-
duced by therapy at distant locations. It is well known
that more primitive cells have a higher expression of
drug efflux pumps [75-77], possess more efficient DNA-
repair mechanisms [78,79], and are more resistant to
hypoxia [47].
Chemotherapy and radiotherapy create a pro-metastatic
microenvironment in bone marrow and other tissues
Besides surgical removal of tumor tissue, chemotherapy
and radiotherapy are the most important and efficient
treatment modalities employed to treat therapy-susceptible
malignancies. The main aim of treatment - to destroy
tumor cells - is unfortunately usually associated with tox-
icity to non-tumor cells and different degrees of tissue and
organ damage. The organ most sensitive to toxic damage
by chemotherapeutics is usually BM. Toxic damage to BM
may somewhat mimic the situation encountered during
conditioning before hematopoietic transplantation, when
BM-residing cells are severely damaged and, in parallel,
several chemoattractants are released in the BM micro-
environment that play a role in chemoattraction and hom-
ing of the infused in the graft normal HSPCs [1,2,46,80].
We postulate that in a similar way, these factors may che-
mottract tumor cells that survived initial treatment.
In support of this notion, as already demonstrated by
us and other groups, exposure of mice to irradiation
[81], cyclophosphamide [80], or vincristine [17,82] upre-
gulates the levels of several chemokines and growth fac-
tors, such as SDF-1, HGF/SF, VEGF, and monocyte
chemotactic protein-1 (MCP-1), in the BM microenvir-
onment. In addition, as we have recently demonstrated,
in vivo exposure of mice to irradiation and cyclophos-
phamide elevates BM expression of S1P and C1P, which
are endowed with strong chemotactic properties againstnormal as well as malignant cells [7,17]. Exposure of BM
to irradiation, similar as to chemotherapeutics, leads to
release of several alarmines (e.g., ATP and UTP) from
the damaged BM cells (manuscript in preparation). We
can assume that a similar response accompanies the
toxic effects of chemotherapy or radiotherapy in other
sensitive organs, including liver and lungs.
All these pro-metastatic factors are released from the
damaged tissues by different mechanisms. Accordingly,
tissue damage-related hypoxia leads to synthesis and re-
lease of, for example, SDF-1, VEGF, and HGF/SF in an
HIF-1α-dependent manner [67,83]. However, this process
requires some time for these factors to be expressed
through gene activation and transcription of mRNA and
subsequent translation of mRNA into proteins. By con-
trast, alarmines or DAMPs (e.g., ATP, UTP, HMGB1, or
S100 molecules) are released immediately from damaged
and “leaky” cells [56,61,72].
Furthermore, it is important to highlight that
chemotherapy- or radiotherapy-associated tissue and
organ damage also activates developmentally early pro-
teolytic cascades, such as the complement cascade
(ComC), coagulation cascade (CoaC), and fibrynolytic
cascade (FibC). It is well known that some of the acti-
vated proteolytic cleavage products of these cascades,
such as C3a, C5a, thrombin, urokinase or uPAR, are dir-
ectly or indirectly involved in cancer metastasis [84-88].
An important mechanism related to chemotherapy- or
radiotherapy-mediated activation of CoaC and ComC is
activation of blood platelets and release of platelet-derived
microvesicles [84,89-91]. These small circular membrane
fragments may transfer several platelet–endothelium cell
adhesion receptors, for example, glycoprotein IIb/IIIa
(CD41), Ib, IaIIa, and P-selectin (CD62P), to the surface of
circulating tumor cells and thus facilitate attachment of
CSCs or DTCs to the endothelium at the site of a future
metastasis [89,92].
In addition to this pro-metastatic, adhesion-mediated ef-
fect, it has been reported that some cytostatics e.g., cyclo-
phosphamide, by exerting direct toxicity to the endothelial
wall, which affects the integrity of the endothelial barrier,
may facilitate seeding of cancer cells into damaged organs
through the disrupted endothelium [80].
Figure 1 depicts our concept postulating creation of a
chemotherapy- or radiotherapy-mediated pro-metastatic
microenvironment in BM and other organs. This un-
wanted side effect is involved mainly in metastasis of
tumor cells to tissues that are highly sensitive to damage
by chemotheraputics as well as toxic doses of radiation
(e.g., BM, liver, and lungs). Since BM tissue is highly sensi-
tive to chemotherapy or radiotherapy, its damage facili-
tates creation of a metastasis-receptive microenvironment
and is responsible for the occurrence of so frequent bone
metastases as seen in the clinical setting.
Figure 1 Chemotherapy or radiotherapy induces a metastasis-receptive microenvironment in various organs. One of the unwanted side
effects of treatment is upregulation of several pro-metastatic and pro-survival factors, such as chemokines (e.g., SDF-1), growth factors (HGF/SF
and VEGF), bioactive sphigophospholipids (S1P and C1P), and alarmines (ATP and UTP) in collateral-damaged tissues and organs. In parallel, in
response to tissue damage, proteolytic cascades, such as the coagulation cascade (CoaC), complement cascade (ComC), and fibrynolytic cascade
(FibC), are activated, which in different ways also enhance the metastasis of cancer cells that survived treatment. These most-resistant-to-therapy,
and thus surviving, cancer cells are usually endowed with high endogenous motility. This mechanism plays an important role, primarily in
metastasis of malignant cells to the tissues susceptible to the toxic effects of chemotherapy or radiotherapy, such as bones, lungs, liver and
abdominal and pelvic cavities.
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therapeutic approaches
The natural propensity of CSCs or DTCs to migrate to dis-
tant metastasis-receptive locations and the fact that one of
the unwanted side effects of chemotherapy or radiotherapy
is induction of a metastasis-promoting microenvironment
points to the important implication that standard treatment
protocols should be followed by anti-metastatic strategies
[61,93,94]. However, this is an obviously difficult task, be-
cause efficient anti-metastatic compounds are not currently
available. One of the reasons for this unfortunate situation
is that several developmental strategies for such drugs arebased on targeting single chemoattractant-specific receptor
axes (e.g., targeting SDF-1–CXCR4 or HGF/SF–c-Met).
This is a somewhat questionable strategy, since tumor cells
may respond simultaneously to several chemotactic factors
and modulators of chemotactic responsiveness, and block-
age of just one axis will be compensated by other un-
affected pro-metastatic factors. The preferred sites of
metastasis are tissues susceptible to damage by chemother-
apy or radiotherapy such as bone marrow, and Figure 2 de-
picts a scenario where chemotherapy or radiotherapy
induces a pro-metastatic microenvironment in bones for
circulating CSCs or DTCs that survived treatment.
Figure 2 Chemotherapy- or radiotherapy-mediated metastasis of cancer cells to bones. Due to upregulation of several homing and
pro-survival factors in response to BM microenvironment damage, circulating cancer cells may find a permissive environment in BM, which can
originate growth of a bone metastasis. Similar mechanism may also operate in pelvic cavity after chemotherapy and lead to spread of ovarian cancer.
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mental models, it has been demonstrated that blockade of
CXCR4 [50], CXCR7 [95], or c-Met [81] receptors by
employing small molecular inhibitors; downregulation of
these receptors by shRNA strategies [95]; in vivo adminis-
tration of blocking antibodies against SDF-1 [50,61,96] or
MCP-1 [80]; or application of S1P-binding aptamers [17]
significantly diminished the process of chemotherapy- or
radiotherapy-related dissemination of tumor cells to vari-
ous organs.
However, the future of potent anti-metastatic drugs
will depend on molecules that interfere with migration
and adhesion processes of CSCs and DTCs downstream
of surface receptors. It is obvious that the tumor specifi-
city of such compounds will be a critical hurdle in devel-
opment of such drugs. However, the simple and sad fact
that metastases are responsible for 90% of cancer-
associated mortalities points to the importance of devel-
oping such compounds for modern pharmacology.
Implications for leukemia and lymphoma therapy
However, while a major focus of this review is on solid
tumors, which may metastasize and thus become un-
wanted inhabitants in BM or other organs, it is obvious
that the same mechanisms may apply for malignant
leukemia and lymphoma cells. As shown in Figure 3,
both γ-irradiation as well as cyclophosphamide adminis-
tration increase in BM expression of SDF-1, HGF/SF,S1P, and C1P, which on the one hand are potent chemo-
tactic factors for tumor cells and, on the other hand, are
potent pro-survival and anti-apoptotic agents for a var-
iety of normal and malignant cells, including leukemia
and lymphoma cells [3,17,80,81].
We propose that chemotherapy-induced BM toxicity
may also have adverse effects on the most primitive
leukemia or lymphoma stem cells. In response to treat-
ment, the BM microenvironment releases several factors
that may promote retention of malignant cells, and some
of them involved in regeneration of marrow tissue may
increase the survival of treatment-resistant cancer cells.
To support this notion, it is well known that SDF-1,
HGF/SF, S1P, and C1P are survival-increasing factors for
many types of cells, including those from hematopoietic
lineages [81,97].
Moreover, one of the treatment strategies in hematopoietic
malignancies currently being explored is release of
leukemia or lymphoma cells from the stem cell niches
they occupy - by blocking the SDF-1–CXCR4 axis [24,98,99]
or by blocking other homing signals to render them
more sensitive to chemotherapeutic agents. Unfortunately,
the upregulation of homing factors in BM as result of
chemotherapy may increase expression of homing signals
and thus retention of the most primitive and therapy-
resistant cells in the BM microenvironment.
Leukemia and lymphoma CSCs and DTCs may also
respond to homing cues in BM tissues of distant bones
Figure 3 Increase in expression of important chemoattractants and pro-survival factors in BM after in vivo exposure to γ-irradiation or
cyclophosphamide treatment. Panel A. Real-time PCR analysis of changes in the expression of mRNA for SDF-1 and SF in murine BM 24 hours
after irradiation (750 cGy) or exposure to cyclophosphamide (200 mg/kg/bw/mouse). The experiment was repeated three times with four
animals/group. Panel B. Mass spectrometry analysis shows that ceramide-1-phosphate (C1P) and sphingosine-1-phosphate (S1P) become
upregulated in murine BM after conditioning for hematopoietic transplantation by lethal irradiation [17]. The data shown in panels A–B represent
the combined results from three independent experiments carried out in triplicate per group.
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microenvironment (e.g., spleen, lymph nodes, and liver).
This may, with time, promote spread of the malignancy.
Implications for ovarian cancer metastasis and therapy
Ovarian cancer has the highest mortality rate among all
the gynecologic tumors and in contrast to many other
hematogenously metastasizing solid tumors disseminate
within the peritoneal cavity [100]. It is often diagnosed at a
late stage after tumor cells are already disseminated within
pelvis. Thus, patients with ovarian cancer usually have at
time of diagnosis locally advanced disease in the pelvic cav-
ity, with continuous extension to uterus, fallopian tube,
and the sigmoid colon. In contrast to prostate cancer, ovar-
ian cancer in rare cases only metastasizes to BM or brain.
It is also a chemotherapy sensitive malignancy. Therefore,
radiotherapy is not a common option for its treatment.
Several genes, growth factors, adhesion molecules, che-
mokines, metalloproteinases and hormones have been re-
ported to play critical role in progression and metastasis
of ovarian cancer [100]. Many of them such as SDF-1,
HGF/SF or S1P may be upregulated in tumor cells and
microenvironment (e.g., ascites) in response to chemo/
radiotherapy (Figure 1) [98-108].
As reported, SDF-1induces rapid intracellular calcium
mobilization and activation of metalloproteinases MMP-2 and MMP-9 which enhance ERK1/2 signaling pathway
leading to increase of cancer cell adhesion. SDF-1 also
increases expression of CXCR4 at both the transcription
and protein levels [102,106]. HGF/SF is another pro-
metastatic factor that may be upregulated by chemo/
radiotherapy, which after binding to tyrosine kinase re-
ceptor c-Met activates mitogenic pathways and thus
plays an important role in tumor growth. Overexpres-
sion of HGF/SF or c-Met in ovarian cancer cells in-
creases expression of α5 and β1 integrins, urokinase and
metalloproteinases (MMP-2 and MMP-9) that have been
shown to increase tumor growth and metastasis [103].
In addition HGF/SF activates also MAPKp42/44 and
PI3K which leads to dissemination of ovarian cells
[103,104]. In addition, HGF functions in morphological
remodeling, invasion and migration of cancer cells, and
decreases the expression of E-cadherin, β-catenin, and
caveolin-1 at the cell membrane, mechanisms essential
in promoting metastasis [106-108]. Finally, evidence ac-
cumulated that S1P signaling is also involved in epithe-
lial ovarian tumorigenesis. This bioactive lipid is elevated
in human ascites [105] and stimulates migration and in-
vasion of ovarian epithelial cancer cells (EOC).
All this supports a concept that treatment of ovarian
cancer should be from beginning combined with anti-
metastatic approaches to lower risk of metastatic side
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ing to investigate if so called metronomic chemotherapy,
based in contrast to traditional chemotherapy on
chronic, equally spaced administration of low doses of
various chemotherapeutic drugs without extended rest
periods that results in lower rate of metastasis/recur-
rence [109], is associated with reduced release of pro-
metastatic factors from damaged organs.
Conclusions
We propose a novel concept whereby the unwanted and
underappreciated side effects of chemotherapy or radio-
therapy create a metastasis-receptive microenvironment
in bones as well as in other organs of the body (e.g., pelvic
cavity). Upregulation of several chemokines, growth fac-
tors, alarmines, bioactive phosphosphingolipids as well as
activation of CoaC, ComS, FibC and metalloproteinases,
in toto, enhances and modulates trafficking and survival of
CSCs and DTCs that survived treatment. This implies a
challenge for modern pharmacology to develop powerful
anti-metastatic compounds that can be combined with
standard chemotherapy and radiotherapy protocols or ap-
plied as a follow up to these protocols.
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